Information on the Total Number of Voting Rights (Denominator) Following the Completion of the LDA Capital Increase

Liege, Belgium, 05 August 2020 – 17:45 CEST –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 159,800 new shares today for a total amount of EUR 3,104,869 following the First Put Option Notice issued on May 29 2020 in the framework of the formal completion of the Company’s capital increase approved by the Board on May 22, 2020 according to the terms of the LDA capital commitment agreement.

Mithra’s EGM Approves Warrant Plan for LDA Capital

Liege, Belgium, 23 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the Company’s Extraordinary General Meeting (EGM) held on 22 July 2020 approved the issuance of 690,000 warrants for the benefit of LDA Capital Ltd. The warrants were issued as part of the transaction announced on April 24 2020.

Publication of a Transparency Notification Received from Alychlo NV

Liege, Belgium, 10 July 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, having its registered seat located at Lembergsesteenweg 19, 9820 Merelbeke, on 9 July 2020.

Publication of a Transparency Notification Received from Ogesip Invest SA

Liege, Belgium, 9 July 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Ogesip Invest SA, having its registered seat located at 1030 Schaerbeek Boulevard du Roi Albert II 37, on 30 June 2020.

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 23 June 2020 – 17:45 CEST –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the following information, following the issuance of 3,421,052 new shares on 23 June 2020 for an amount of EUR 65.0 million in gross proceeds in the framework of the private placement via an accelerated bookbuild offering publicly announced on 18 June 2020.

Notice of Extraordinary Shareholders’ Meeting on 22th July 2020 Regarding Proposed Warrant Plans

Liege, Belgium, 19 June 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the publication of the invitation to its Extraordinary General Shareholders’ Meeting (EGM) that will be held on Wednesday July 22 2020 at 2:00 PM (CET) in Flémalle 57 rue de l’Expansion (Belgium).

The agenda of this Meeting will mainly consider the issuance of two warrant plans subject to the shareholder’s approval : (i) one for the benefit of LDA Capital Ltd whereby a maximum of 690,000 warrants would be issued within the framework of the transaction announced on the 24th April 2020[1], and (ii) another for the benefit of reference shareholders (“Share Lending Warrants”) as further detailed in the supporting documentation for a maximum of 300,000 warrants.

The special reports of the board of directors and of the statutory auditor established pursuant to provisions 7:180, 7: 191 and 7:193 of the Belgian Companies and Associations Code, the notice for the EGM for the shareholders, including all details on how to participate to this Meeting and the supporting documents are available on the Company website.

[1] Press release Mithra, 24/04/2020

Mithra Launches Capital Increase By Means of a Private Placement via an Accelerated Bookbuild Offering and Provides an Update on its Financing Strategy

  • Launch of a capital increase of approximately EUR 55 million by means of a private placement via an accelerated bookbuild offering
  • Loan of EUR 20 million secured, in addition to the recent capital commitment agreement with LDA for up to EUR 50 million
  • Last building blocks in the Company’s financing strategy in becoming a commercial company

Liège, Belgium, 18 June 2020, 14:30 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces today the launch of a capital increase of approximately EUR 55 million by means of a private placement via an accelerated bookbuild offering (the “Private Placement”).

Mithra Issues First Put Option Notice Under Capital Agreement with LDA Capital

Liege, Belgium, 05 June 2020 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that following the signature of the capital commitment agreement with LDA Capital Limited announced on April 24, 2020, the Board of Directors approved on May 22, 2020 an increase to the Company’s capital by means of an issuance of new ordinary shares through authorized capital. The first put option notice was issued last Friday, May 29, 2020, according to the terms of the capital commitment agreement.


 

 

Mithra Obtains a Capital Commitment Agreement of EUR 50 Million from Partner LDA Capital

Liege, Belgium, 24 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into a capital commitment agreement with LDA Capital Limited, a Los Angeles based global investment group with expertise in cross border transactions in life science sector.

Mithra Releases 2019 Annual Report and Invitation to its Securities holders’ Meeting

Liege, Belgium, 22 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2019 Annual Report and the invitation to its Ordinary and Extraordinary General Securities holders.

2019 Annual Report

The Annual Report which outlines Mithra’s achievements in 2019 includes the following information:

  • Overview of Mithra’s R&D pipeline and Letter to Shareholders;
  • Highlights of Mithra’s Strategy and Outlook for 2020;
  • Management Report;
  • Remuneration Report;
  • Financial statements and notes.

The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website investors.mithra.com. In case of interpretation differences, the French version will prevail.

François Fornieri, CEO Mithra Women’s Health, commented:

2019 marked our 20th anniversary and was exceptional in more ways than one. We recorded a strong turnover increase, achieved key milestones in both clinical development and international growth, and a CDMO that successfully moved into commercial production. In 2020, despite this unprecedented situation caused by Covid-19, our teams are determined to do everything possible to meet our ambitious challenges.”

 



 

General Shareholders’ meeting

Mithra is pleased to invite its securities holders to its Ordinary and Extraordinary General Shareholder’s meeting that will be held on Friday May 22 2020 at 2:00 PM (CEST).

The notice for the General Shareholder’s Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.

Exceptional organisational arrangements due to Covid-19 have been made